LEXX (Lexaria Bioscience) ROCE %: -149.50% (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LEXX Lexaria Bioscience Corp LEXX
41 GF Score
Price $8.84
GF Value $5.38
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Lexaria Bioscience ROCE %?

Lexaria Bioscience LEXX +11.60% 41 ROCE % is -149.50% as of May. 2026. GuruFocus rates LEXX with a GF Score™ of 41/100 and a GF Value™ of $5.38 (Significantly Overvalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lexaria Bioscience's annualized ROCE % for the quarter that ended in May. 2026 was -149.50%.

Lexaria Bioscience  (NAS:LEXX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lexaria Bioscience ROCE % Related Terms

Lexaria Bioscience ROCE % Historical Data

* Premium members only.

The historical data trend for Lexaria Bioscience's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexaria Bioscience ROCE % Chart

Lexaria Bioscience Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -72.37 -63.79 -124.98 -108.70 -227.37

Lexaria Bioscience Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -247.75 -271.10 -173.06 -106.90 -149.50
LEXX
41GF Score
Lexaria Bioscience Corp LEXX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lexaria Bioscience ROCE % Calculation

Lexaria Bioscience's annualized ROCE % for the fiscal year that ended in Aug. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Aug. 2025 )  (A: Aug. 2024 )(A: Aug. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Aug. 2025 )  (A: Aug. 2024 )(A: Aug. 2025 )
=-11.881/( ( (8.868 - 1.099) + (4.175 - 1.493) )/ 2 )
=-11.881/( (7.769+2.682)/ 2 )
=-11.881/5.2255
=-227.37 %

Lexaria Bioscience's ROCE % of for the quarter that ended in May. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: May. 2026 )  (Q: Feb. 2026 )(Q: May. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: May. 2026 )  (Q: Feb. 2026 )(Q: May. 2026 )
=-7.976/( ( (6.487 - 0.215) + (4.781 - 0.383) )/ 2 )
=-7.976/( ( 6.272 + 4.398 )/ 2 )
=-7.976/5.335
=-149.50 %

(1) Note: The EBIT data used here is four times the quarterly (May. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -149.50% mean?
Lexaria Bioscience (LEXX) has a ROCE % of -149.50% as of May. 2026.
Is Lexaria Bioscience's ROCE % too high?
Lexaria Bioscience's current ROCE % is -149.50%. Overall, Lexaria Bioscience has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's ROCE % compare to CTXR and PTN?
Lexaria Bioscience's ROCE % of -149.50% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Lexaria Bioscience's current ROCE % is -149.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.38, compared to a current price of $8.84 — trading 64.3% above its estimated fair value. The current ROCE % is -149.50%. Lexaria Bioscience's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current ROCE % is -149.50% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lexaria Bioscience (LEXX) Overvalued in 2026?

Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be overvalued. The current stock price of $8.84 is trading 64.3% above its estimated GF Value™ of $5.38. GuruFocus considers Lexaria Bioscience to be Significantly Overvalued.

Key valuation signals for LEXX:

  • ROCE %: -149.50%
  • GF Value™: $5.38 vs. price of $8.84 (64.3% above fair value)
  • GF Score™: 41/100 with 5 warning signs

No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lexaria Bioscience Business Description

Address 740 McCurdy Road, No. 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
41GF Score

Get the complete analysis for LEXX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.84
Price
$5.38
GF Value